3B BlackBio Dx Ltd Fundamental Analysis
3B BlackBio Dx Ltd (3BBLACKBIO.BO) shows moderate financial fundamentals with a PE ratio of 16.35, profit margin of 44.57%, and ROE of 20.10%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 81.2/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 3BBLACKBIO.BO's fundamental strength across five key dimensions:
Efficiency Score
Excellent3BBLACKBIO.BO demonstrates superior asset utilization.
Valuation Score
Moderate3BBLACKBIO.BO shows balanced valuation metrics.
Growth Score
Moderate3BBLACKBIO.BO shows steady but slowing expansion.
Financial Health Score
Excellent3BBLACKBIO.BO maintains a strong and stable balance sheet.
Profitability Score
Moderate3BBLACKBIO.BO maintains healthy but balanced margins.
Key Financial Metrics
Is 3BBLACKBIO.BO Expensive or Cheap?
P/E Ratio
3BBLACKBIO.BO trades at 16.35 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 3BBLACKBIO.BO's PEG of 149.89 indicates potential overvaluation.
Price to Book
The market values 3B BlackBio Dx Ltd at 3.13 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 16.87 times EBITDA. This signals the market has high growth expectations.
How Well Does 3BBLACKBIO.BO Make Money?
Net Profit Margin
For every $100 in sales, 3B BlackBio Dx Ltd keeps $44.57 as profit after all expenses.
Operating Margin
Core operations generate 42.41 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $20.10 in profit for every $100 of shareholder equity.
ROA
3B BlackBio Dx Ltd generates $17.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
3B BlackBio Dx Ltd generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
3B BlackBio Dx Ltd generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
3BBLACKBIO.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
16.35
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
149.89
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.13
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.18
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.001
vs 25 benchmark
Current Ratio
Current assets to current liabilities
6.25
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
0.17
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How 3BBLACKBIO.BO Stacks Against Its Sector Peers
| Metric | 3BBLACKBIO.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 16.35 | 29.63 | Better (Cheaper) |
| ROE | 20.10% | 223.00% | Weak |
| Net Margin | 44.57% | -38669.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.82 | Strong (Low Leverage) |
| Current Ratio | 6.25 | 4.30 | Strong Liquidity |
| ROA | 17.00% | -379.00% (disorted) | Strong |
3BBLACKBIO.BO outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews 3B BlackBio Dx Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation